Steven Quay - Academia.edu (original) (raw)

Steven Quay

Uploads

Papers by Steven Quay

Research paper thumbnail of MR imaging of the genitourinary tract with a paramagnetic contrast agent: Phase I and II trials of S-FDF

Research paper thumbnail of Compositions and methods for directed ultrasound imaging

Research paper thumbnail of Pyridoxamine chelating compounds, manganese (II) chelates and their use as NMRI contrast agents

Research paper thumbnail of Use of chelate complexes

Research paper thumbnail of Pharmaceutical compositions comprising oxytocin or an analog for the treatment of autism

Research paper thumbnail of Methods of Breast Cancer Detection

Research paper thumbnail of Method for treating colorectal carcinoma using a taxane/tocopherol formulation

Research paper thumbnail of Nucleic Acid Compounds for Inhibiting WNT Gene Expression and Uses Thereof

Research paper thumbnail of Intranasal Administration of Glucose-Regulating Peptides

Research paper thumbnail of Stable pharmaceutical dosage forms of teriparatide

Research paper thumbnail of Nicked or Gapped Nucleic Acid Molecules and Uses Thereof

Research paper thumbnail of Cyanocobalamin Low Viscosity Aqueous Formulations for Intranasal Delivery

Research paper thumbnail of Method of treating bladder carcinoma using a Taxane/Tocopherol formulation

Research paper thumbnail of Nucleic Acid Compounds for Inhibiting Apob Gene Expression and Uses Thereof

Research paper thumbnail of Nucleic Acid Compounds for Inhibiting PLK1 Gene Expression and Uses Thereof

Research paper thumbnail of Amino Acid Lipids and Uses Thereof

Research paper thumbnail of Method of treatment of a metabolic disease using intranasal administration of exendin peptide

Research paper thumbnail of Demarcation of myocardial ischemia: magnetic susceptibility effect of contrast medium in MR imaging

Radiology, 1989

Dysprosium diethylenetriamine-pentaacetic acid-bis (methylamide) (DTPA-BMA), a new nonionic contr... more Dysprosium diethylenetriamine-pentaacetic acid-bis (methylamide) (DTPA-BMA), a new nonionic contrast medium for magnetic resonance (MR) imaging, produces signal loss on T2-weighted images because of induced magnetic field gradients. The potential of this agent to delineate myocardial ischemia was investigated in 10 rats with acute (30 minutes) occlusion of the left coronary artery. T2-weighted MR images were acquired before and for 1 hour after intravenous administration of 1 mmol/kg of Dy-DTPA-BMA. Before administration of the contrast medium, signal intensity (SI) in the ischemic region was significantly greater than that in the normal myocardium; however, the borders of the ischemic region were not consistently distinct. The contrast medium caused marked decrease in SI of normal myocardium (18% +/- 3% of the control value), only slight decrease in the jeopardized region (76% +/- 6% of the control value), and no discernible effects on heart rate or blood pressure. Substantial contrast between normal and ischemic myocardium persisted for 1 hour. Moderate signal loss was observed in skeletal muscle. Dy-DTPA-BMA has the potential to demarcate the myocardial area in jeopardy as a region of high signal intensity because it erases signal preferentially in the normal myocardium.

Research paper thumbnail of Analytical Validation of the ForeCYTE Breast Health Test

Journal of the American Society of Cytopathology, 2013

Introduction: The ForeCYTE Breast Health Test provides a 10-year and lifetime breast cancer risk ... more Introduction: The ForeCYTE Breast Health Test provides a 10-year and lifetime breast cancer risk stratification using family history of breast and ovarian cancer, personal reproductive history, and cytological evaluation of exfoliated cells present in nipple aspirate fluid (NAF) in the risk stratification algorithm developed by TyrerCuzick. Materials and Methods: Specimens of NAF are collected on membrane filters with one of two FDA-cleared biopsy instruments, the Halo or the Mammary Aspiration Specimen Cytology Test (MASCT) System devices, are fixed upon collection by spraying the membrane filters with a 0.1 mL mist of Saccomanno's fixative. The specimen filters are processed in situ for NAF protein using a colloidal gold assay with a limit of detection of 0.1 ng of protein (corresponding to 1 pL of NAF) and a linear range to 1,000 ng. The filters are then stained with a modified Papanicolaou stain and morphological criteria applied to establish a diagnosis. Results: Spiked MCF-7 breast cancer cells demonstrate quantitative recovery (94.7%) in the range of 1-10 cancer cells/membrane filter with a sensitivity for identifying a cellular specimen of 100% at 4-100 cells/membrane and 75% at 2 cells/membrane and 50% at 1 cell /membrane. If hyperplasia is noted and morphology is inadequate

Research paper thumbnail of Preclinical evaluation of MnDPDP: new paramagnetic hepatobiliary contrast agent for MR imaging

Research paper thumbnail of MR imaging of the genitourinary tract with a paramagnetic contrast agent: Phase I and II trials of S-FDF

Research paper thumbnail of Compositions and methods for directed ultrasound imaging

Research paper thumbnail of Pyridoxamine chelating compounds, manganese (II) chelates and their use as NMRI contrast agents

Research paper thumbnail of Use of chelate complexes

Research paper thumbnail of Pharmaceutical compositions comprising oxytocin or an analog for the treatment of autism

Research paper thumbnail of Methods of Breast Cancer Detection

Research paper thumbnail of Method for treating colorectal carcinoma using a taxane/tocopherol formulation

Research paper thumbnail of Nucleic Acid Compounds for Inhibiting WNT Gene Expression and Uses Thereof

Research paper thumbnail of Intranasal Administration of Glucose-Regulating Peptides

Research paper thumbnail of Stable pharmaceutical dosage forms of teriparatide

Research paper thumbnail of Nicked or Gapped Nucleic Acid Molecules and Uses Thereof

Research paper thumbnail of Cyanocobalamin Low Viscosity Aqueous Formulations for Intranasal Delivery

Research paper thumbnail of Method of treating bladder carcinoma using a Taxane/Tocopherol formulation

Research paper thumbnail of Nucleic Acid Compounds for Inhibiting Apob Gene Expression and Uses Thereof

Research paper thumbnail of Nucleic Acid Compounds for Inhibiting PLK1 Gene Expression and Uses Thereof

Research paper thumbnail of Amino Acid Lipids and Uses Thereof

Research paper thumbnail of Method of treatment of a metabolic disease using intranasal administration of exendin peptide

Research paper thumbnail of Demarcation of myocardial ischemia: magnetic susceptibility effect of contrast medium in MR imaging

Radiology, 1989

Dysprosium diethylenetriamine-pentaacetic acid-bis (methylamide) (DTPA-BMA), a new nonionic contr... more Dysprosium diethylenetriamine-pentaacetic acid-bis (methylamide) (DTPA-BMA), a new nonionic contrast medium for magnetic resonance (MR) imaging, produces signal loss on T2-weighted images because of induced magnetic field gradients. The potential of this agent to delineate myocardial ischemia was investigated in 10 rats with acute (30 minutes) occlusion of the left coronary artery. T2-weighted MR images were acquired before and for 1 hour after intravenous administration of 1 mmol/kg of Dy-DTPA-BMA. Before administration of the contrast medium, signal intensity (SI) in the ischemic region was significantly greater than that in the normal myocardium; however, the borders of the ischemic region were not consistently distinct. The contrast medium caused marked decrease in SI of normal myocardium (18% +/- 3% of the control value), only slight decrease in the jeopardized region (76% +/- 6% of the control value), and no discernible effects on heart rate or blood pressure. Substantial contrast between normal and ischemic myocardium persisted for 1 hour. Moderate signal loss was observed in skeletal muscle. Dy-DTPA-BMA has the potential to demarcate the myocardial area in jeopardy as a region of high signal intensity because it erases signal preferentially in the normal myocardium.

Research paper thumbnail of Analytical Validation of the ForeCYTE Breast Health Test

Journal of the American Society of Cytopathology, 2013

Introduction: The ForeCYTE Breast Health Test provides a 10-year and lifetime breast cancer risk ... more Introduction: The ForeCYTE Breast Health Test provides a 10-year and lifetime breast cancer risk stratification using family history of breast and ovarian cancer, personal reproductive history, and cytological evaluation of exfoliated cells present in nipple aspirate fluid (NAF) in the risk stratification algorithm developed by TyrerCuzick. Materials and Methods: Specimens of NAF are collected on membrane filters with one of two FDA-cleared biopsy instruments, the Halo or the Mammary Aspiration Specimen Cytology Test (MASCT) System devices, are fixed upon collection by spraying the membrane filters with a 0.1 mL mist of Saccomanno's fixative. The specimen filters are processed in situ for NAF protein using a colloidal gold assay with a limit of detection of 0.1 ng of protein (corresponding to 1 pL of NAF) and a linear range to 1,000 ng. The filters are then stained with a modified Papanicolaou stain and morphological criteria applied to establish a diagnosis. Results: Spiked MCF-7 breast cancer cells demonstrate quantitative recovery (94.7%) in the range of 1-10 cancer cells/membrane filter with a sensitivity for identifying a cellular specimen of 100% at 4-100 cells/membrane and 75% at 2 cells/membrane and 50% at 1 cell /membrane. If hyperplasia is noted and morphology is inadequate

Research paper thumbnail of Preclinical evaluation of MnDPDP: new paramagnetic hepatobiliary contrast agent for MR imaging

Log In